Subscribe Now
Forgot Password?

Weekly News, Analysis, and Commentary

Legal & Regulatory Feature

FLXfit Expandable Cage / Courtesy of Expanding Orthopedics, Inc.

FDA Clears Expandable Cage For Smaller Patients

Walter Eisner • Wed, October 4th, 2017

Print this article

In good news for smaller patients, the FDA has granted 510(k) clearance to Israeli-based Expanding Orthopedics, Inc., to market its interbody FLXfit15 expandable cage.

The device was cleared on September 15, 2017 after notification was submitted to the FDA in May. The company stated the device will offer surgeon's more flexibility with different length options for "infinitely adjustable expansion and lordosis correction of up to 4mm and 15°.”

The company's CEO Ofer Bokobza said, the device will "further enhance the anatomical fit with its 15° lordosis and the shorter footprint version (32mm) will offer great flexibility in treating patients with smaller anatomies."

While there is a major trend towards minimally invasive procedures in spine, Dale Binke, EOI's VP of U.S. sales said, "There is an inherent challenge in inserting a large interbody cage that restores lumbar lordosis while controlling sagittal and coronal alignment."

He said the companies FLXfit has already provided the "ultimate" expandable TLIF solution, combining the "best-in-class footprint that can be delivered through a MIS [minimally invasive surgery] window and a unique expansion mechanism that restores lordosis. With the FLXfit15, EOI's engineering team has pushed the envelope a step further by combining an articulating cage with optimal footprint which can be easily delivered and expanded in a controlled manner up to 4mm and 15° of lordotic restoration."

According to the company, the FLXfit is indicated for interbody fusion "in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). These patients should be skeletally mature and have completed six months of non-operative treatment."

The device is intended to be used with supplemental spinal fixation system and with autogenous bone graft. It is important to note, said the company, that the device must be applied in combination with posterior fusion system such as the EOI XPED Pedicle Screw System.

Send to a Friend

The article link will be sent to the email address you provide

Your Name (required)

Your Email (required)

Friend's Email (required)

Comments

Leave a Reply

Name

Email Address (will not be published)

Website

Comment: